info@Selagine.com
312-526-3725
News
FDA Grants IND Clearance for Immunoglobulin Eye Drops to Treat Dry Eye Disease Patients in a Phase II Clinical Study
Illinois Medicine Magazine: From Research to Real-World Impact
Topical Biologics In Ophthalmology?
Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease
Grifols enters into global collaboration and licensing agreement with Selagine to develop immunoglobulin eye drops to treat dry eye disease
Dry eye disease: New treatment on the horizon
Antibody-based eye drops show promise for treating dry eye disease
Scientific Publications
Safety and tolerability of pooled human immune globulins after topical ophthalmic administration in New Zealand White rabbits
Attenuation of neutrophil adhesion and formation of neutrophil extracellular traps by pooled human immune globulin
Adjunct Topical Human Immunoglobulin IgG Therapy in Dry Eye Disease
Ocular graft-versus-host disease: Experience, incidence, and treatment outcomes at a university-based tertiary care ophthalmology center
Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease
Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops (“Triple Play”) in Recalcitrant Immunological Ocular Surface Diseases
SELAGINE Inc, 2315 W Taylor St, Ste A, Chicago, IL 60612
@ Copyright 2023 SELAGINE INC | Privacy Statement
